ResMed Archives | Page 2 of 3 | Be Korea-savvy
Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports

Over 480 Million People Estimated to Have COPD, World’s Third Deadliest Disease, ResMed Study Reports

BARCELONA, Spain, Sept. 4 (Korea Bizwire) — Over 480 million people worldwide likely suffer from chronic obstructive pulmonary disease, or COPD, according to a late-breaking abstract led by ResMed (NYSE: RMD, ASX: RMD) presented at the European Respiratory Society Congress today.1 This figure is 22–126% higher than today’s most cited estimates, which range from 212–392 [...]

ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions

ResMed to Acquire MEDIFOX DAN, a German Leader in Out-of-Hospital Software Solutions

SAN DIEGO and HILDESHEIM, Germany, June 14 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced a definitive agreement to acquire privately held MEDIFOX DAN, a German leader in out-of-hospital software solutions for providers in major settings across the care continuum, from Hg, a leading software and services investor. MEDIFOX DAN’s clinical, financial, and [...]

ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference

ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference

SAN DIEGO, May 25 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bernstein Strategic Decisions Conference on Wednesday, June 1, 2022, beginning at approximately 1:30 p.m. (Eastern Daylight Time) at the New York Hilton Midtown in New York City. More [...]

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study

SAN FRANCISCO, May 18 (Korea Bizwire) — Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study led by ResMed (NYSE: RMD, ASX: RMD) and presented at the American Thoracic Society’s annual International Conference. The retrospective, observational study analyzed the [...]

ResMed Announces Leadership Change

ResMed Announces Leadership Change

SAN DIEGO, May 5 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effective immediately. Rob Douglas, President and Chief Operating Officer, has been appointed interim President, Sleep and Respiratory Care.  [...]

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022

ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2022

SAN DIEGO, April 28 (Korea Bizwire) — ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2022. Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com Third Quarter 2022 Highlights All comparisons are to the prior year period Revenue increased by 12% to [...]

ResMed Announces Participation in the 24th Annual Macquarie Australia Conference

ResMed Announces Participation in the 24th Annual Macquarie Australia Conference

SAN DIEGO, April 27 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced Brett Sandercock, chief financial officer, will present virtually at the Macquarie Australia Conference on Tuesday, May 3, 2022, beginning at approximately 8:45 a.m. (Australian Eastern Standard Time) via video webcast. More information about this event, including access to the live webcast, [...]

ResMed Announces Participation in the KeyBanc Capital Markets’ Life Sciences & MedTech Investor Forum

ResMed Announces Participation in the KeyBanc Capital Markets’ Life Sciences & MedTech Investor Forum

SAN DIEGO, March 17 (Korea Bizwire) — ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the KeyBanc Capital Markets’ Life Sciences & MedTech Investor Forum on Tuesday, March 22, 2022, beginning at approximately 1:30 p.m. (Eastern Daylight Time) via webcast. More information about [...]